Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly Depreciation & Amortization (CF) of $27000.0 in Q3 2025, down 10.0% quarter-over-quarter from $30000.0 in Q2 2025, and up 8.0% on a YoY basis from $25000.0 in Q3 2024.
Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $27000.0 for Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) rose 8.0% year-over-year to $27000.0; the TTM figure through Dec 2025 stood at $84000.0 (down 12.5% YoY), while the FY2024 annual figure was $96000.0, up 43.28% from the prior year.
- Depreciation & Amortization (CF) was $27000.0 for Q3 2025 at Dianthus Therapeutics, down from $30000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $532000.0 in Q3 2021 to a low of $19000.0 in Q3 2023.
- Historically, Depreciation & Amortization (CF) has averaged $253611.1 across 5 years, with a median of $225500.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) slumped 95.97% in 2023, then soared 31.58% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $515000.0 in 2021, then declined by 9.51% to $466000.0 in 2022, then sank by 95.71% to $20000.0 in 2023, then rose by 30.0% to $26000.0 in 2024, then climbed by 3.85% to $27000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $27000.0 (Q3 2025), $30000.0 (Q2 2025), and $27000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 23,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Mar 31, 2023 | 421,000.00 |
| Mar 31, 2023 | 421,000.00 |